The advancement of targeted therapeutic approaches, such as those focusing on inhibiting vascular endothelial growth factor (VEGF) signaling, BRAF and MEK pathways, as well as blocking epidermal growth factor receptor (EGFR) signaling, in addition to the integration of immunotherapy, in combination with conventional chemotherapy, has demonstrated enhanced efficacy in terms of both progression-free survival (PFS) and overall survival (OS) within certain specific subgroups of metastatic colorectal cancer patient populations (3). This evidence concerns the gene EGFR and metastatic colorectal cancer.